Bigstock The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) Nov. 3 for Bravecto (fluralaner) chewable tablets to treat New World screwworm (NWS) infestations, or myiasis, in dogs and puppies. The authorization is based on scientific evidence indicating the drug may be effective when used as directed, with its potential benefits outweighing known and potential risks. Fluralaner belongs to the isoxazoline class of antiparasitic drugs commonly used in dogs. The agency previously approved Bravecto for the treatment of flea and tick infestation in canine patients. Although exposure risk remains low for most U.S. dogs, those living in or traveling to areas with confirmed cases should be monitored for signs, such as visible maggots or foul odors in wounds or body openings. For up-to-date U.S. case information, see the U.S. Department of Agriculture’s dashboard of Confirmed Detections of New World Screwworm.
